Using canine osteosarcoma as a model to assess efficacy of novel therapies: Can old dogs teach us new tricks?

Advances in Experimental Medicine and Biology

Volumn 804, Issue , 2014, Pages 237-256

  Rodriguez, Carlos O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aerosol chemotherapy; Aerosol gemcitabine; Aerosol interleukin 2; Dog cancer model; Large animal model; Muramyl tripeptide phosphatidylethanolamine; Novel therapy; Osteosarcoma; Thiomolybdate

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; INTERLEUKIN 2; LIPOSOME ENCAPSULATED MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE; PLACEBO; RECOMBINANT INTERLEUKIN 2; TETRATHIOMOLYBDIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MIFAMURTIDE; MOLYBDENUM; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE;

AEROSOL; AMPUTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANINE MODEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; LIPOSOMAL DELIVERY; LUNG LESION; LUNG METASTASIS; MEDICAL ONCOLOGIST; METASTASIS; METASTASIS FREE SURVIVAL; MICROMETASTASIS; NEBULIZATION; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; VETERINARY MEDICINE; ANIMAL; ANIMAL DISEASE; BONE TUMOR; CHILD; DOG; DOG DISEASE; LUNG TUMOR; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA; CANIS FAMILIARIS;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; AEROSOLS; ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; DEOXYCYTIDINE; DOG DISEASES; DOGS; HUMANS; INTERLEUKIN-2; LUNG NEOPLASMS; MOLYBDENUM; OSTEOSARCOMA; PHOSPHATIDYLETHANOLAMINES; SIGNAL TRANSDUCTION;

EID: 84907170285     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-04843-7_13     Document Type: Article

References (123)

1. Anderson H, Lund B, Bach F et al (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung-cancer - A phase-II study. J Clin Oncol 12:1821–1826
2. Anderson PM, Wiseman GA, Erlandson L et al (2005) Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 11:6895–6900
3. Ando T, Ichikawa J, Okamoto A et al (2005) Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines. J Orthop Res 23:964–969
4. Bacon NJ, Ehrhart NR, Dernell WS et al (2008) Use of alternating administration of carbo-platin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). JAVMA 232:1504–1510
5. Bailey D, Erb H, Williams L et al (2003) Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. J Vet Intern Med 17:199–205
6. Batschinski K, Dervisis NG, Kitchell BE (2012) Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. Vet Comp Oncol. 2012 Sep 18. DOI: 10.1111/j.1476-5829.2012.00355
7. Berg J, Gebhardt MC, Rand WM (1997) Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 79:1343–1350
8. Berg J, Weinstein MJ, Schelling SH et al (1992) Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 200:2005–2008
9. Berg J, Weinstein MJ, Springfi eld DS et al (1995) Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 206:1555–1560
10. Bergman PJ, Macewen EG, Kurzman ID et al (1996) Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 10:76–81
11. Bezault J, Walsh C, Tarcsay L et al (1993) Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immunomodulatory agents and chemotherapeutic drugs. In Vivo 7:487–491
12. Bielack SS, Kempf-Bielack B, Delling G et al (2002) Prognostic factors in high-grade osteo-sarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790
13. Boston SE, Ehrhart NP, Dernell WS et al (2006) Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985-2004). J Am Vet Med Assoc 228:1905–1908
14. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V et al (1991) Initial therapy of patients with Wilson’s disease with tetrathiomolybdate. Arch Neurol 48:42–47
15. Brewer GJ, Merajver SD (2002) Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper – a review. Integr Cancer Ther 1:327–337
16. Chun R, Garrett LD, Henry C et al (2005) Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. J Am Anim Hosp Assoc 41:382–387
17. Chun R, Kurzman ID, Couto CG et al (2000) Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study. J Vet Intern Med 14:495–498
18. Cox C, Teknos TN, Barrios M et al (2001) The role of copper suppression as an antiangio-genic strategy in head and neck squamous cell carcinoma. Laryngoscope 111:696–701
19. Cozzi PJ, Bajorin DF, Tong W et al (1999) Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 5:2629–2637
20. De Brito Galvao JF, Kisseberth WC, Murahari S et al (2012) Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines. Am J Vet Res 73:1262–1272
21. Dominguez PA, Dervisis NG, Cadile CD et al (2009) Combined gemcitabine and carboplatin therapy for carcinomas in dogs. J Vet Intern Med 23:130–137
22. Duan X, Jia SF, Koshkina N et al (2006) Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer 106:1382–1388
23. Elpiner AK, Brodsky EM, Hazzah TN et al (2011) Single-agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas. Vet Comp Oncol 9:260–268
24. Fidler IJ, Kleinerman ES (1984) Lymphokine-activated human-blood monocytes destroy tumor-cells but not normal-cells under cocultivation conditions. J Clin Oncol 2:937–943
25. Fidler IJ, Schroit AJ (1988) Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta 948:151–173
26. Fidler IJ, Sone S, Fogler WE et al (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous-injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci U S A 78:1680–1684
27. Fidler IJ, Sone S, Fogler WE et al (1982) Efficacy of liposomes containing a lipophilic mur-amyl di peptide derivative for activating the tumoricidal properties of alveolar macrophages in-vivo. J Biol Response Mod 1:43–56
28. Freise KJ, Martin-Jimenez T (2006) Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. J Vet Pharmacol Ther 29:137–145
29. Freise KJ, Martin-Jimenez T (2006) Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion. J Vet Pharmacol Ther 29:147–152
30. Funk J, Schmitz G, Failing K et al (2005) Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. Cancer Immunol Immunother 54:87–92
31. Gagnadoux F, Leblond V, Vecellio L et al (2006) Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer chemotherapy and pharmacology 58:237–244
32. Gandhi V, Plunkett W, Du M et al (2002) Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20:665–673
33. Gordon N, Arndt CS, Hawkins DS et al (2005) Fas expression in lung metastasis from osteo-sarcoma patients. J Pediat Hematol Oncol 27:611–615
34. Gordon N, Koshkina N V, Jia S-F et al (2007) Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 13:4503–4510
35. Grunewald R, Kantarjian H, Du M et al (1992) Gemcitabine in leukemia - a phase-I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406–413
36. Guma SR, Lee DA, Yu L et al (2013) Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediat Blood Cancer 61(4):618–626
37. Helfand SC, Soergel SA, Macwilliams PS et al (1994) Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs. Cancer Immunol Immunother 39:84–92
38. Hershey AE, Kurzman ID, Forrest LJ et al (1999) Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 5:2653–2659
39. Herzog CE (2005) Overview of sarcomas in the adolescent and young adult population. J Pediat Hematol Oncol 27:215–218
40. Hibbs JB (1974) Discrimination between neoplastic and non-neoplastic cells invitro by activated macrophages. J Natl Cancer Inst 53:1487–1492
41. Hillers KR, Dernell WS, Lafferty MH et al (2005) Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986-2003). J Am Vet Med Assoc 226:1364–1367
42. Huang P, Chubb S, Hertel LW et al (1991) Action of 2′,2′-difl uorodeoxycytidine on dna-synthesis. Cancer Res 51:6110–6117
43. Huland E, Heinzer H, Jorres RA et al (2004) Therapeutic approaches in metastatic renal cell carcinoma: local immunotherapy. Der Urologe Ausg A 43(Suppl 3):S140–S144
44. Jones PD, De Lorimier LP, Kitchell BE et al (2003) Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc 39:463–467
45. Jongeward SJ (1985) Primary bone-tumors. Vet Clin Small Anim Pract 15:609–641
46. Kawai M, Esumi Y, Ishizaki M et al (1995) Metabolism of gemcitabine in rat and dog. Xenobiotica 25:405–416
47. Kent MS, Strom A, London CA et al (2004) Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appen-dicular osteosarcoma in dogs. J Vet Intern Med 18:540–544
48. Khan MK, Miller MW, Taylor J et al (2002) Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia 4:164–170
49. Khanna C, Hasz DE, Klausner JS et al (1996) Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res 2:721–734
50. Khanna C, Waldrep JC, Anderson PM et al (1997) Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution. J Pharm Pharmacol 49:960–971
51. Kim KK, Kawar NM, Singh RK et al (2011) Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines. Gynecol Oncol 122:183–189
52. Kleinerman ES, Erickson KL, Schroit AJ et al (1983) Activation of tumoricidal properties in human-blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 43:2010–2014
53. Kleinerman ES, Gano JB, Johnston DA et al (1995) Effi cacy of liposomal muramyl tri-peptide (Cgp 19835a) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 18:93–99
54. Kleinerman ES, Jia SF, Griffi n J et al (1992) Phase-II study of liposomal muramyl tripeptide in osteosarcoma - the cytokine cascade and monocyte activation following administration. J Clin Oncol 10:1310–1316
55. Kleinerman ES, Murray JL, Snyder JS et al (1989) Activation of tumoricidal properties in monocytes from cancer-patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res 49:4665–4670
56. Kosarek CE, Kisseberth WC, Gallant SL et al (2005) Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. J Vet Intern Med 19:81–86
57. Koshkina NV, Khanna C, Mendoza A et al (2007) Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 5:991–999
58. Koshkina N V, Kleinerman ES (2005) Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 116:458–463
59. Koshkina NV, Waldrep JC, Roberts LE et al (2001) Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7:3258–3262
60. Kozicki AR, Robat C, Chun R et al (2013) Adjuvant therapy with carboplatin and pamidro-nate for canine appendicular osteosarcoma. Vet Comp Oncol. 10 MAY 2013, DOI: 10.1111/vco.12040
61. Kraegel SA, Madewell BR, Simonson E et al (1991) Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 199:1057–1059
62. Kurzman ID, Macewen EG, Rosenthal RC et al (1995) Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1:1595–1601
63. Kurzman ID, Shi F, Macewen EG (1993) In-vitro and in-vivo canine mononuclear cell production of tumor-necrosis-factor induced by muramyl peptides and lipopolysaccharide. Vet Immunol Immunopathol 38:45–56
64. Lafl eur EA, Koshkina NV, Stewart J et al (2004) Increased Fas expression reduces the meta-static potential of human osteosarcoma cells. Clin Cancer Res 10:8114–8119
65. Leblanc AK, Ladue TA, Turrel JM et al (2004) Unexpected toxicity following use of gem-citabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 45:466–470
66. Lemarie E, Vecellio L, Hureaux J et al (2011) Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study. J Aerosol Med Pulm Drug Deliv 24:261–270
67. Macewen EG, Kurzman ID, Rosenthal RC et al (1989) Therapy for osteo-sarcoma in dogs with intravenous-injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst 81:935–938
68. Madewell BR, Leighton RL, Theilen GH (1978) Amputation and doxorubicin for treatment of canine and feline osteogenic-sarcoma. Eur J Cancer 14:287–293
69. Maeda M, Knowles RD, Kleinerman ES (1991) Muramyl tripeptide phosphatidylethanol-amine encapsulated in liposomes stimulates monocyte production of tumor-necrosis-factor and interleukin-1 invitro. Cancer Commun 3:313–321
70. Marchi E, Alinari L, Tani M et al (2005) Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 104:2437–2441
71. Marconato L, Lorenzo RM, Abramo F et al (2008) Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol 6:90–101
72. Marconato L, Zini E, Lindner D et al (2011) Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 238:1004–1010
73. Mauldin GN, Matus RE, Withrow SJ et al (1988) Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 2:177–180
74. Mcmahon M, Mathie T, Stingle N et al (2011) Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma. J Vet Intern Med 25:511–517
75. Mcmahon MB, Bear MD, Kulp SK et al (2010) Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. Am J Vet Res 71:799–808
76. Merimsky O, Meller I, Flusser G et al (2000) Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 45:177–181
77. Merimsky O, Meller I, Kollender Y et al (1998) Palliative effect of gemcitabine in osteosar-coma resistant to standard chemotherapy. Eur J Cancer 34:1296–1297
78. Merimsky O, Meller I, Kollender Y et al (2000) Gemcitabine in bone sarcoma resistant to Doxorubicin-based chemotherapy. Sarcoma 4:7–10
79. Meyers PA, Schwartz CL, Krailo MD et al (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J Clin Oncol 26:633–638
80. Morello E, Buracco P, Martano M et al (2001) Bone allografts and adjuvant cisplatin for the treatment of canine appendicular osteosarcoma in 18 dogs. J Small Anim Pract 42:61–66
81. Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007–1008
82. Mule JJ, Yang JC, Afreniere RL et al (1987) Identifi cation of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 139:285–294
83. Navid F, Willert JR, Mccarville MB et al (2008) Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113:419–425
84. O’brien MG, Straw RC, Withrow SJ et al (1993) Resection of pulmonary metastases in canine osteosarcoma: 36 cases (1983-1992). Vet Surg 22:105–109
85. Okuno S, Edmonson J, Mahoney M et al (2002) Phase II trial of gemcitabine in advanced sarcomas. Cancer 94:3225–3229
86. Okuno S, Ryan LM, Edmonson JH et al (2003) Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 97:1969–1973
87. Pan Q, Kleer CG, Van Golen KL et al (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62:4854–4859
88. Paoloni M, Davis S, Lana S et al (2009) Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 10:625
89. Papa MZ, Mule JJ, Rosenberg SA (1986) Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Res 46:4973–4978
90. Parke A, Bhattacherjee P, Palmer RM et al (1988) Characterization and quantifi cation of copper sulfate-induced vascularization of the rabbit cornea. Am J Pathol 130:173–178
91. Perez-Manga G, Lluch A, Alba E et al (2000) Gemcitabine in combination with doxorubicin in advanced breast cancer: fi nal results of a phase II pharmacokinetic trial. J Clin Oncol 18:2545–2552
92. Phillips B, Powers BE, Dernell WS et al (2009) Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. J Am Anim Hosp Assoc 45:33–38
93. Raju KS, Alessandri G, Ziche M et al (1982) Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst 69:1183–1188
94. Rizzieri DA, Bass AJ, Rosner GL et al (2002) Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol 20:674–679
95. Rizzieri DA, Ibom VK, Moore JO et al (2003) Phase I evaluation of prolonged-infusion gem-citabine with fl udarabine for relapsed or refractory acute myelogenous leukemia. Clin Cancer Res 9:663–668
96. Rodriguez CO, Crabbs TA, Wilson DW et al (2010) Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv 23:197–206
97. Rosenberg SA, Mule JJ, Spiess PJ et al (1985) Regression of established pulmonary metasta-ses and subcutaneous tumor mediated by the systemic administration of high-dose recombi-nant interleukin 2. J Exp Med 161:1169–1188
98. Saam DE, Liptak JM, Stalker MJ et al (2011) Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006). J Am Vet Med Assoc 238:195–206
99. Santoro A, Bredenfeld H, Devizzi L et al (2000) Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study. J Clin Oncol 18:2615–2619
100. Selting K, Essman S, Reinero C et al (2011) Targeted combined aerosol chemotherapy in dogs and radiologic toxicity grading. J Aerosol Med Pulm Drug Deliv 24:43–48
101. Shapiro W, Fossum TW, Kitchell BE et al (1988) Use of cisplatin for treatment of appendicu-lar osteosarcoma in dogs. J Am Vet Med Assoc 192:507–511
102. Shi FS, Macewen EG, Kurzman ID (1993) In-vitro and in-vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation. Cancer Res 53:3986–3991
103. Shipley LA, Brown TJ, Cornpropst JD et al (1992) Metabolism and disposition of gem-citabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20:849–855
104. Siegel JP, Puri RK (1991) Interleukin-2 toxicity. J Clin Oncol 9:694–704
105. Simcock JO, Withers SS, Prpich CY et al (2012) Evaluation of a single subcutaneous infusion of carboplatin as adjuvant chemotherapy for dogs with osteosarcoma: 17 cases (2006-2010). J Am Vet Med Assoc 241:608–614
106. Skorupski KA, Uhl JM, Szivek A et al (2013) Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial. Vet Comp Oncol. 2013 Oct 4. DOI: 10.1111/vco.12069
107. Smith BW, Kurzman ID, Schultz KT et al (1993) Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteo-sarcoma cells. Cancer Biother 8:137–144
108. Smith MA, Seibel NL, Altekruse SF et al (2010) Outcomes for children and adolescents with cancer: challenges for the twenty-fi rst century. J Clin Oncol 28:2625–2634
109. Spodnick GJ, Berg J, Rand WM et al (1992) Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 200:995–999
110. Straw RC, Withrow SJ, Richter SL et al (1991) Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 5:205–210
111. Thompson JP, Fugent MJ (1992) Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc 200:531–533
112. Turner AI, Hahn KA, Rusk A et al (2006) Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma. J Vet Intern Med 20:1384–1388
113. Vail DM, Kurzman ID, Glawe PC et al (2002) STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 50:131–136
114. Van Golen KL, Bao L, Brewer GJ et al (2002) Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. Neoplasia 4:373–379
115. Van Moorsel CJ, Peters GJ, Pinedo HM (1997) Gemcitabine: future prospects of single-agent and combination studies. Oncologist 2:127–134
116. Vial T, Descotes J (1992) Clinical toxicity of interleukin-2. Drug Saf 7:417–433
117. Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP et al (2006) Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs 17:859–864
118. Withrow SJ, Thrall DE, Straw RC et al (1993) Intraarterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer 71:2484–2490
119. Worth LL, Lafl eur EA, Jia SF et al (2002) Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 9:823–827
120. Zak D, Styler MJ, Rosenbluth JZ et al (2005) Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma. Clin Adv Hematol Oncol 3:297–299, discussion 300-292
121. Zinzani PL, Baliva G, Magagnoli M et al (2000) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18:2603–2606
122. Zinzani PL, Bendandi M, Stefoni V et al (2000) Value of gemcitabine treatment in heavily pretreated Hodgkin’s disease patients. Haematologica 85:926–929
123. Zinzani PL, Magagnoli M, Bendandi M et al (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9:1351–1353